This Article Full Text Full Text (PDF) All Versions of this Article: 34/10/2387    most recent 01.STR.0000088642.07691.15v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Santamaría, A. Articles by Fontcuberta, J. Search for Related Content PubMed PubMed Citation Articles by Santamaría, A. Articles by Fontcuberta, J. Related Collections Arterial thrombosis Thrombosis risk factors Acute Cerebral Infarction

(Stroke. 2003;34:2387.)
© 2003 American Heart Association, Inc.

Original Contributions

Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels

A. Santamaría, MD; A. Oliver, MD; M. Borrell, PhD; J. Mateo, MD, PhD; R. Belvis, MD; J. Martí-Fábregas, MD, PhD; R. Ortín;; I. Tirado, PharmD; J.C. Souto, MD, PhD J. Fontcuberta, MD, PhD

From the Hemostasis and Thrombosis Unit, Hematology Department (A.S., M.B., J.M., R.O., I.T., J.C.S., J.F.), Neurology Department, (R.B., J.M.-F.), and Fundación Puigvert (A.O.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Correspondence to Dr A. Santamaría, Department of Hematology, Hospital de la Santa Creu i Sant Pau, C/ Sant Antoni Ma Claret, 167, 08025-Barcelona, Spain. E-mail msantamaria{at}hsp.santpau.es

Background and Purpose— Recently, a novel procarboxypeptidase B–like proenzyme, called thrombin-activatable fibrinolysis inhibitor (TAFI), has been described. It plays an important role in the delicate balance between coagulation and fibrinolysis. TAFI leads to potent inhibition of tissue plasminogen activator–induced fibrinolysis. The relevance of TAFI in thromboembolic disease is unclear. We have investigated the risk of ischemic stroke (IS) in relation to plasma levels of functional TAFI.

Methods— In a case-control study, we enrolled 264 individuals; 114 had IS, and 150 were recruited as controls who were age and sex matched and had no history of arterial disease. The individuals supplied information on their personal and family histories of cardiovascular diseases and conventional cardiovascular risk factors. Functional TAFI assays were performed by use of a method based on the activation of TAFI with thrombin-thrombomodulin and the measure of the TAFI activity generated. Other hemostatic parameters assayed were factor VIIIc, anti-phospholipid antibodies,fibrinogen, factor V Leiden, and the prothrombin gene G20210A mutations (PT20210A).

Results— Functional TAFI levels were significantly higher in patients with IS (113.7±25%; range, 57% to 209%) than in controls (102.6±19%). The odds ratio for IS in patients with functional TAFI levels >120% was 5.7 (95% confidence interval, 2.3 to 14.1).

Conclusions— We found that functional TAFI levels in plasma (>120%) increased the risk of IS 6-fold. Further studies should elucidate the physiological role of TAFI in arterial disease and possibly provide clues to therapeutic approaches.

Key Words: fibrinolysis • stroke, ischemic • thrombosis

This article has been cited by other articles:

				O. Salomon, D. M. Steinberg, N. Koren-Morag, D. Tanne, and U. Seligsohn Reduced incidence of ischemic stroke in patients with severe factor XI deficiency Blood, April 15, 2008; 111(8): 4113 - 4117. [Abstract] [Full Text] [PDF]

				C. Ladenvall, A. Gils, K. Jood, C. Blomstrand, P. J. Declerck, and C. Jern Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 955 - 962. [Abstract] [Full Text] [PDF]

				J.-M. Olivot, J. Labreuche, M. Aiach, P. Amarenco, and for the GENIC Investigators Soluble Thrombomodulin and Brain Infarction: Case-Control and Prospective Study Stroke, August 1, 2004; 35(8): 1946 - 1951. [Abstract] [Full Text] [PDF]